rHuEPO and granulocyte colony-stimulating factor (G-CSF) stand as stalwart agents in addressing these cytopenias, fostering enhanced tolerability and adherence to antiviral therapy in cirrhosis patients. This evidence concerns the gene CSF3 and Cirrhosis.